Brought to you by 
Ranbaxy gets rights to Sirtex's liver cancer treatment
24 May 2012
Executive Summary
Ranbaxy Laboratories has licensed exclusive rights from Australian cancer company Sirtex Medical to market SIR-Spheres for inoperable metastatic liver tumors from primary colorectal cancer in India, Bangladesh, Sri Lanka, and Nepal.
Deal Industry
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ranbaxy gets rights to Sirtex's liver cancer treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice